Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) – Premium Triple GH Research Peptide

Welcome to Liaocheng Yixin Company, your trusted source for premium tesamorelin cjc-1295 ipamorelin 12mg blend for research. As a specialized peptide synthesis manufacturer operating from our facility at No. 9 Lushan Road, Dongcheng Street, Liaocheng Economic and Technological Development Zone, Shandong Province, we provide high-quality research compounds for the global scientific community.

This 12mg triple blend combines three mechanistically distinct growth hormone-releasing peptides: Tesamorelin (an FDA-approved GHRH analog with documented efficacy in reducing visceral adipose tissue), CJC-1295 (a stabilized GHRH analog), and Ipamorelin (a selective ghrelin receptor agonist) . Tesamorelin has demonstrated 15-18% reductions in visceral adipose tissue in large randomized controlled trials for HIV-associated lipodystrophy, making it a unique research tool for fat metabolism studies . Our tesamorelin cjc-1295 ipamorelin 12mg blend for research offers investigators a convenient, precisely formulated tool for endocrine signaling, metabolic research, and receptor pharmacology studies. tesamorelin cjc-1295 ipamorelin 12mg blend for research

What is the Tesamorelin, CJC-1295 & Ipamorelin Blend?

This 12mg lyophilized blend contains three research peptides that work through complementary mechanisms at the hypothalamic-pituitary axis:

Tesamorelin is a synthetic 44-amino acid peptide analogue of growth hormone-releasing hormone (GHRH) with an N-terminal modification that enhances stability and resistance to enzymatic degradation . CJC-1295 without DAC is a tetrasubstituted GHRH analog with four amino acid substitutions that protect it from rapid enzymatic degradation . Ipamorelin is a pentapeptide ghrelin mimetic known for its highly selective GH release with minimal stimulation of cortisol or prolactin .tesamorelin cjc-1295 ipamorelin 12mg blend for research

Mechanism of Action in Research

The blend combines three distinct pathways to produce GH release through multiple amplification mechanisms :

GHRH Receptor Pathway (Tesamorelin & CJC-1295)

Both Tesamorelin and CJC-1295 bind the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled adenylyl cyclase signaling . This elevates intracellular cAMP, activates protein kinase A (PKA), and drives GH gene transcription and granule exocytosis. The half-lives differ significantly: Tesamorelin has a half-life of approximately 26 minutes after subcutaneous injection, while CJC-1295 without DAC has a half-life of roughly 30 minutes .

Ghrelin Receptor Pathway (Ipamorelin)

Ipamorelin activates GHS-R1a, a class A GPCR that couples primarily through Gq/11-alpha . This activates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium stores and activate protein kinase C (PKC). The calcium surge triggers immediate exocytosis of pre-formed GH vesicles .

Triple Convergence and Distinct Signaling Profiles

The combination offers unique research advantages :

• Complementary GHRH analogs: Tesamorelin and CJC-1295 both stimulate GHRH receptors but have distinct pharmacokinetic profiles, allowing researchers to study pulse frequency and amplitude effects

• Selective vs. potent pathways: Ipamorelin provides clean GH release with minimal cortisol/prolactin elevation, making it valuable for selective pathway research

• Documented metabolic effects: Tesamorelin provides a well-documented reference point for metabolic studies (15-18% VAT reduction), unlike the unapproved CJC-1295/ipamorelin combination 

Scientific Research Applications

Metabolic and Visceral Fat Research

Tesamorelin has the strongest evidence base among the three components. In large randomized controlled trials of HIV patients with lipodystrophy, tesamorelin demonstrated 15-18% reductions in visceral adipose tissue (VAT) and improvements in liver enzymes . Research has also shown tesamorelin decreases muscle fat infiltration (myosteatosis) and increases muscle density . This makes the blend valuable for studying fat metabolism, liver health, and muscle quality in research models.

Growth Hormone Axis and Receptor Signaling

The combination of two GHRH analogs (tesamorelin and CJC-1295) with a GHRP (ipamorelin) allows researchers to investigate:

• Synergistic effects of multiple GHRH receptor agonists

• GHRH vs. ghrelin pathway interactions

• Receptor desensitization and recovery kinetics

• Pulsatile vs. sustained GH exposure mechanisms

• tesamorelin cjc-1295 ipamorelin 12mg blend for research

Body Composition and Endocrine Studies

Ipamorelin’s selective profile makes it valuable for investigating the effects of GH release without confounding cortisol or prolactin elevation . Tesamorelin’s documented lean body mass increases provide a reference point for muscle protein synthesis studies .

Safety and Side Effect Research

The distinct side-effect profiles of each component provide avenues for safety research :

• Tesamorelin: Injection site reactions, fluid retention, arthralgias, glucose intolerance, increased IGF-1

• CJC-1295/Ipamorelin: Transient flushing, water retention, injection site reactions

Important Research Considerations

FDA Approval Status: Tesamorelin (brand name Egrifta SV) received FDA approval in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy . It is not approved for general weight loss or body composition improvement in otherwise healthy adults. CJC-1295 plus ipamorelin is a compounded, unapproved combination with no published human randomized controlled trials; its research use rests on mechanistic reasoning .

Regulatory Status: GHRH analogs including CJC-1295 and growth hormone-releasing peptides including ipamorelin are listed under WADA’s Prohibited List in the peptide hormone category. Tesamorelin is also prohibited in competitive sport .

Dosing Literature: Tesamorelin is dosed at 2 mg subcutaneously once daily per its FDA label. CJC-1295 (without DAC) is commonly compounded at 200-300 mcg per injection combined with ipamorelin at 200-300 mcg . Compounded doses are not derived from approved labeling.

Why Choose Liaocheng Yixin Company?

When sourcing tesamorelin cjc-1295 ipamorelin 12mg blend for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC analysis. Our blend meets ≥99% purity standards. Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Appearance: White lyophilized powder

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture. Lyophilized forms should be stored at 2-8°C before reconstitution. After reconstitution with bacteriostatic water, use within 14-28 days refrigerated. Do not freeze reconstituted solution .

• Form: Lyophilized powder for research use

• tesamorelin cjc-1295 ipamorelin 12mg blend for research

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. Mass Spectrometry for molecular weight confirmation

5. Packaged in sterile conditions for research use

6. tesamorelin cjc-1295 ipamorelin 12mg blend for research

: How does this triple blend work in research compared to dual GHRH/GHRP blends?

A: This blend combines two GHRH analogs (tesamorelin and CJC-1295) with a GHRP (ipamorelin). Tesamorelin is the only FDA-approved GHRH analog with documented 15-18% visceral fat reduction in large RCTs, while CJC-1295 provides an alternative GHRH receptor engagement profile . This triple combination allows researchers to study the effects of distinct GHRH analogs alongside selective ghrelin receptor activation.

: What is the key distinction between tesamorelin and CJC-1295 in this blend?

A: Tesamorelin is FDA-approved with published human RCT data demonstrating visceral fat reduction and muscle quality improvement . CJC-1295 has no published human RCTs for the no-DAC version but is commonly used in peptide clinic protocols. Both act on the same receptor but have different stability and half-life characteristics.

: What are the key research applications for this triple blend?

A: This blend is used in metabolic research (visceral fat, liver fat, muscle quality studies), growth hormone axis research, receptor signaling studies, and body composition investigations.

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. This blend is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications .

When you need premium tesamorelin cjc-1295 ipamorelin 12mg blend for research for your endocrine, metabolic, or receptor pharmacology studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust. tesamorelin cjc-1295 ipamorelin 12mg blend for research